Literature DB >> 28104261

Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease.

Ana Valado1, Maria João Leitão2, António Martinho3, Rui Pascoal4, João Cerqueira5, Inês Correia6, Sónia Batista7, Lívia Sousa7, Inês Baldeiras8.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation and axonal degeneration of the central nervous system and a leading cause of disability in young adults. The matrix metalloproteinases in general and specially gelatinase B/metalloproteinase-9 (MMP-9) plays a role in the pathogenesis of multiple sclerosis.
OBJECTIVE: To investigate the presence of the MMP-9 -1562C/T polymorphism in a Portuguese population of MS patients and assess its impact in susceptibility and course of the disease. The relation of MMP-9 serum levels with the polymorphism and with clinical and therapeutic factors will also be assessed.
METHODS: Our study included 355 Caucasian individuals distributed as MS patients (n=169) and controls (n=186). Samples were genotyped for -1562C/T polymorphism by PCR-RFLP analysis. MMP-9 concentration in serum was analyzed using a commercially available enzyme-linked immunosorbent assay.
RESULTS: A significant increase in T-allele frequency was found in female MS patients, but not in the total patient population. No association between the presence of the polymorphism and disease progression was found. MMP-9 serum concentrations were increased in patients, and although not influenced by the -1562C/T polymorphism, were modified by INF-beta therapy.
CONCLUSION: Although we did not find an association of this polymorphism with disease susceptibility or prognosis, MMP-9 appears to be a good therapeutic response marker for multiple sclerosis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IFN-beta therapy; MMP-9; Multiple sclerosis; Serum; −1562C/T polymorphism

Mesh:

Substances:

Year:  2016        PMID: 28104261     DOI: 10.1016/j.msard.2016.12.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  4 in total

1.  Galangin Inhibits LPS-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent AP-1 and FoxO1 Activation in Rat Brain Astrocytes.

Authors:  Chien-Chung Yang; Li-Der Hsiao; Chuen-Mao Yang
Journal:  J Inflamm Res       Date:  2020-11-20

2.  CSF/serum matrix metallopeptidase-9 ratio discriminates neuro Behçet from multiple sclerosis.

Authors:  Alessandra Aldinucci; Elena Bonechi; Tiziana Biagioli; Anna M Repice; Mario M D'Elios; Lorenzo Emmi; Giacomo Emmi; Elena Silvestri; Alessandro Barilaro; Clara Ballerini
Journal:  Ann Clin Transl Neurol       Date:  2018-03-10       Impact factor: 4.511

3.  Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis.

Authors:  Mina Mohammadhosayni; Arezou Khosrojerdi; Keivan Lorian; Saeed Aslani; Danyal Imani; Bahman Razi; Farhad Babaie; Shahram Torkamandi
Journal:  BMC Neurol       Date:  2020-05-29       Impact factor: 2.474

Review 4.  The Seaweed Diet in Prevention and Treatment of the Neurodegenerative Diseases.

Authors:  Leonel Pereira; Ana Valado
Journal:  Mar Drugs       Date:  2021-02-26       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.